Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 13 de 13
Filtrer
2.
Nicotine Tob Res ; 2024 Apr 03.
Article de Anglais | MEDLINE | ID: mdl-38566367

RÉSUMÉ

INTRODUCTION: We compare real-world trends in population-level cigarette discontinuation rates among adults (ages ≥21) who smoked cigarettes, by electronic nicotine delivery systems (ENDS) use. AIMS AND METHODS: U.S nationally representative data from adults in the Population Assessment of Tobacco and Health (PATH) Study (2013/14-2021, Waves 1-6) who smoked cigarettes in the past 30 days (P30D) were analyzed (n = 13 640). The exposure was P30D ENDS use. The outcome was P30D cigarette discontinuation at biennial follow-up. Weighted trend analyses were conducted to test for differences in cigarette discontinuation trends by ENDS use. RESULTS: Between 2013/14 and 2015/16, cigarette discontinuation rates were both 16% for those who used ENDS and for those who did not; between 2018/19 and 2021, rates were ~30% for those who used ENDS and ~20% for those who did not; the time by ENDS use interaction was significant. CONCLUSIONS: The relationship between adults' ENDS use and cigarette discontinuation in the context of an expanded ENDS marketplace, new tobacco regulatory actions, and COVID-19 differs from the relationship in earlier years. IMPLICATIONS: It is important for public health decisions to be informed by research based on the contemporary ENDS marketplace and circumstances.

3.
J Am Geriatr Soc ; 71(7): 2308-2325, 2023 07.
Article de Anglais | MEDLINE | ID: mdl-37029710

RÉSUMÉ

BACKGROUND: Depression affected 5.7% of people aged 60 years and over prior to the pandemic and has increased by approximately 28%. The aim of this study is to identify and describe factors associated with depressive symptoms, the diagnostic assessment instruments and interventions used to evaluate and treat depression in adults aged 60 years and older since the onset of the COVID-19 pandemic. METHODS: Four electronic databases were systematically searched to identify eligible studies published since the beginning of the COVID-19 pandemic. A total of 832 articles were screened, of which 53 met the inclusion criteria. RESULTS: Factors contributing to depressive symptoms in older adults prior to the pandemic were grouped into the following categories: sociodemographic characteristics (i.e., being female); loneliness and weak social support; limitations in daily functioning, physical activity and neurocognitive impairment; and clinical factors. The following groups of factors directly related to the pandemic were found: stress-related factors and feelings or worries related to the pandemic; information access (e.g., receiving news about COVID-19 through the media); factors directly related to COVID-19 (e.g., having infected acquaintances); and factors related to the measures that were taken to reduce the spread of COVID-19 (e.g., confinement measures). The most frequently used instrument to assess depressive symptoms was the Geriatric Depression Scale Short Form (GDS-SF). Four studies implemented interventions during the pandemic that led to significant reductions in depressive symptoms and feelings of loneliness. CONCLUSIONS: Improved understanding of pandemic-associated risk factors for depression can inform person-cantered care. It is important continued mental healthcare for depression for older adults throughout crises, such as the COVID-19 pandemic. Remote delivery of mental healthcare represents an important alternative during such times. It is crucial to address depression in older adults (which often causes disability), since the pandemic situation has increased depressive symptoms in this population.


Sujet(s)
COVID-19 , Humains , Femelle , Adulte d'âge moyen , Sujet âgé , Mâle , COVID-19/épidémiologie , Dépression/épidémiologie , Pandémies , Émotions , Solitude
4.
Tob Control ; 32(4): 480-488, 2023 07.
Article de Anglais | MEDLINE | ID: mdl-34732539

RÉSUMÉ

OBJECTIVE: This scoping review provides an overview of the existing literature on biomarkers of exposure from electronic nicotine delivery systems (ENDS) use and identifies gaps in existing knowledge. DATA SOURCES: We searched two international databases (PubMed and Web of Science) to identify relevant studies published from August 2013 to February 2021. DATA SELECTION: Studies were included if they assessed and compared biomarkers of exposure between exclusive ENDS users, non-users, exclusive cigarette smokers, dual users of ENDS and cigarettes or cigarette smokers who switch to ENDS. DATA EXTRACTION AND SYNTHESIS: Of the 5074 studies identified, 188 studies met criteria and were selected for full-text screening. Of these, 27 studies were selected for inclusion and data extraction. CONCLUSIONS: Consistent, although limited, evidence shows that exclusive ENDS users have elevated levels of biomarkers of certain volatile organic compounds (VOCs; eg, acrylamide and acrylonitrile), metals (eg, cadmium and selenium) and propylene glycol compared with non-users; however, evidence for biomarkers of other toxicants (eg, acrolein, benzene and chromium) is mixed. Biomarkers of most VOCs are lower in ENDS users compared with cigarette smokers, and cigarette smokers who switch to ENDS consistently show reductions in VOC biomarkers. Evidence comparing metal exposures from exclusive ENDS use, cigarette smoking and dual use is mixed and depends on the metal. ENDS and e-liquid characteristics as well as use patterns may be associated with elevated exposure to VOCs and metals. Additional rigorous, controlled studies can assess biomarker exposures from ENDS use and inform the overall risk-benefit of ENDS use for different user populations.


Sujet(s)
Fumer des cigarettes , Dispositifs électroniques d'administration de nicotine , Produits du tabac , Humains , Nicotine , Marqueurs biologiques
5.
BMJ Open ; 12(10): e065610, 2022 10 26.
Article de Anglais | MEDLINE | ID: mdl-36288844

RÉSUMÉ

INTRODUCTION: Depression is a common mental disorder and is a major cause of years lived with disability. The COVID-19 pandemic has caused an increase in the prevalence of depression worldwide. Our aim is to identify and synthesise the determinants of depression, the diagnostic assessment tools used to evaluate depression, and the interventions carried out since the beginning of the COVID-19 pandemic in the population aged 60 and older. METHODS AND ANALYSIS: A systematic review of the literature will be conducted. The following databases will be searched: CINAHL Plus with Full Text, MedicLatina, MEDLINE with Full Text, and Psychology and Behavioural Sciences Collection. The search strategy will include the following Medical Subject Headings or similar terms: "Depression", "Depressive Disorder", "Depressive Symptoms", "Older Adults", "Aging", "Elderly", Pandemic" and "COVID-19". Two independent reviewers will ascertain whether the resulting articles meet inclusion and exclusion criteria, and perform the analysis of data quality. Disagreements will be resolved by a third reviewer. All studies reported between December 2019 and March 2022 meeting the following criteria will be included: studies in adults aged 60 and over, and articles written in English, Portuguese, Spanish or German. Information on determinants of depression, assessment instruments used to assess depressive symptoms and/or interventions to decrease depression are reported. Studies will not be excluded based on geographical area study context (eg, community, culture or specific environment). All studies related to diagnostic assessment, care planning and/or intervention strategies specifically for older adults with depression will be included. ETHICS AND DISSEMINATION: As only secondary data will be analysed, no ethical approval is required for this study. This scientific article is a systematic review protocol for which data have not yet been extracted or analysed. The results will be disseminated through peer-reviewed publications. PROSPERO REGISTRATION NUMBER: CRD42022299775.


Sujet(s)
COVID-19 , Troubles mentaux , Humains , Adulte d'âge moyen , Sujet âgé , COVID-19/épidémiologie , Pandémies , Plan de recherche , Littérature de revue comme sujet
6.
Toxicol Appl Pharmacol ; 434: 115813, 2022 01 01.
Article de Anglais | MEDLINE | ID: mdl-34838608

RÉSUMÉ

Serious adverse health effects have been reported with the use of vaping products, including neurologic disorders and e-cigarette or vaping product use-associated lung injury (EVALI). Vitamin E acetate, likely added as a diluent to cannabis-containing products, was linked to EVALI. Literature searches were performed on vitamin E and vitamin E acetate-associated neurotoxicity. Blood brain barrier (BBB) penetration potential of vitamin E and vitamin E acetate were evaluated using cheminformatic techniques. Review of the literature showed that the neurotoxic potential of inhalation exposures to these compounds in humans is unknown. Physico-chemical properties demonstrate these compounds are lipophilic, and molecular weights indicate vitamin E and vitamin E acetate have the potential for BBB permeability. Computational models also predict both compounds may cross the BBB via passive diffusion. Based on literature search, no experimental nonclinical studies and clinical information on the neurotoxic potential of vitamin E via inhalation. Neurotoxic effects from pyrolysis by-product, phenyl acetate, structurally analogous to vitamin E acetate, suggests vitamin E acetate has potential for central nervous system (CNS) impairment. Cheminformatic model predictions provide a theoretical basis for potential CNS permeability of these inhaled dietary ingredients suggesting prioritization to evaluate for potential hazard to the CNS.


Sujet(s)
Syndromes neurotoxiques/anatomopathologie , Vapotage , Vitamine E/administration et posologie , Barrière hémato-encéphalique/métabolisme , Humains , Structure moléculaire , Vitamine E/composition chimique , Vitamine E/métabolisme
9.
Am J Clin Pathol ; 146(5): 627-631, 2016 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-27744342

RÉSUMÉ

OBJECTIVES: Gastrointestinal infections by cytomegalovirus (CMV) and adenovirus may complicate hematopoietic stem cell transplantation (HSCT). Although CMV and adenovirus produce recognizable cytopathic changes, these changes may be subtle or focal. The value of viral immunohistochemistry in detecting infection in HSCT recipients when cytopathic changes are not identified has not been demonstrated. METHODS: H&E-stained sections from gastrointestinal biopsy specimens were reviewed by three pathologists. Cases were classified as negative, suspicious, or positive for CMV and/or adenovirus infection based on the presence or absence of viral inclusions. Viral immunohistochemistry was performed, and the results were compared with the interpretations of H&E-stained sections. RESULTS: Four of 104 cases contained viral inclusions confirmed by immunohistochemistry: two were infected with CMV, and two were positive for adenovirus. All three reviewers correctly classified both immunopositive CMV cases on H&E evaluation. However, all reviewers missed the diagnosis of adenovirus on H&E assessment in one case. CONCLUSIONS: In HSCT recipients, cytopathic changes of adenovirus may be easily missed in H&E-stained sections of gastrointestinal biopsy specimens. Thus, the routine use of adenovirus immunohistochemistry in all cases is recommended. Both cases of CMV infection were apparent on H&E evaluation, so the judicious use of immunohistochemical stains for CMV in selected cases may be considered.


Sujet(s)
Infections à Adenoviridae/diagnostic , Adenoviridae/immunologie , Infections à cytomégalovirus/diagnostic , Cytomegalovirus/immunologie , Maladies gastro-intestinales/diagnostic , Transplantation de cellules souches hématopoïétiques/effets indésirables , Adenoviridae/génétique , Adenoviridae/isolement et purification , Infections à Adenoviridae/virologie , Adulte , Sujet âgé , Biopsie , Cytomegalovirus/génétique , Cytomegalovirus/isolement et purification , Infections à cytomégalovirus/virologie , Femelle , Maladies gastro-intestinales/virologie , Tube digestif/virologie , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen , Études rétrospectives , Jeune adulte
11.
Am J Surg Pathol ; 39(12): 1661-7, 2015 Dec.
Article de Anglais | MEDLINE | ID: mdl-26448188

RÉSUMÉ

Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy. Clinical findings and symptoms were noted for each patient, and endoscopic findings were recorded for those who underwent colonoscopic examination. Hematoxylin and eosin-stained sections from colonic biopsy samples were evaluated for histologic patterns of injury. Twenty-three (46%) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). Fourteen patients underwent colonoscopic examination with mucosal biopsy. Twelve (86%) of these had colitis characterized by intraepithelial lymphocytosis, crypt cell apoptosis, and neutrophilic infiltration of crypt epithelium. Eleven patients had symptoms severe enough to warrant drug withdrawal, including 9 who were also treated with corticosteroids. Idelalisib commonly causes diarrheal symptoms in patients undergoing therapy for B-cell neoplasia, which may be severe in nearly 20% of patients. Characteristic histologic features include the combination of intraepithelial lymphocytosis and crypt cell apoptosis, often accompanied by neutrophils. Discontinuation of the drug results in symptomatic improvement and resolution of histologic changes.


Sujet(s)
Antinéoplasiques/effets indésirables , Colite/anatomopathologie , Côlon/anatomopathologie , Muqueuse intestinale/anatomopathologie , Leucémie chronique lymphocytaire à cellules B/traitement médicamenteux , Lymphome malin non hodgkinien/traitement médicamenteux , Inhibiteurs de protéines kinases/effets indésirables , Purines/effets indésirables , Quinazolinones/effets indésirables , Hormones corticosurrénaliennes/usage thérapeutique , Sujet âgé , Sujet âgé de 80 ans ou plus , Apoptose/effets des médicaments et des substances chimiques , Marqueurs biologiques/analyse , Biopsie , Phosphatidylinositol 3-kinases de classe I/antagonistes et inhibiteurs , Phosphatidylinositol 3-kinases de classe I/métabolisme , Colite/induit chimiquement , Colite/traitement médicamenteux , Colite/métabolisme , Côlon/composition chimique , Côlon/effets des médicaments et des substances chimiques , Coloscopie , Diarrhée/induit chimiquement , Femelle , Humains , Immunohistochimie , Muqueuse intestinale/composition chimique , Muqueuse intestinale/effets des médicaments et des substances chimiques , Leucémie chronique lymphocytaire à cellules B/enzymologie , Hyperlymphocytose/induit chimiquement , Lymphome malin non hodgkinien/enzymologie , Mâle , Adulte d'âge moyen , Thérapie moléculaire ciblée , Récidive , Études rétrospectives , Indice de gravité de la maladie , Résultat thérapeutique
12.
Diagn Cytopathol ; 43(9): 747-50, 2015 Sep.
Article de Anglais | MEDLINE | ID: mdl-26154021

RÉSUMÉ

Riedel thyroiditis is a rare fibrosing disorder characterized by extension of the fibroinflammatory process beyond the thyroid capsule. Due to the nature of this lesion, fine-needle aspiration often yields scant material and may be interpreted as non-diagnostic. In this report, we describe cytologic features that allow the cytopathologist to favor a diagnosis of Riedel thyroiditis, thereby guiding appropriate further work-up and management.


Sujet(s)
Glande thyroide/anatomopathologie , Thyroïdite/diagnostic , Cytoponction , Humains , Inflammation/diagnostic , Inflammation/anatomopathologie , Mâle , Adulte d'âge moyen , Thyroïdite/anatomopathologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE